Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate


Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being conducted after discussions with the FDA and is effec (US Food Recalls) More More

Similar stories

Lawmakers Seek Clarity From FDA on Recall of Lifesaving Drug - Regulatory Focus

Lawmakers Seek Clarity From FDA on Recall of Lifesaving Drug  Regulatory Focus

Posted on 18 October 2019 | 2:00 am | Google News

Sanders, other lawmakers want answers on recall of Takeda drug - STAT

Sanders, other lawmakers want answers on recall of Takeda drug  STAT

Posted on 18 October 2019 | 2:00 am | Google News

Recall of Takeda's Natpara leaves patients in health limbo - FiercePharma

Recall of Takeda's Natpara leaves patients in health limbo  FiercePharma

Posted on 16 September 2019 | 2:00 am | Google News

Northfork Bison E. Coli Outbreak Spurs Recall - Food Poisoning News

Northfork Bison E. Coli Outbreak Spurs Recall  Food Poisoning News

Posted on 16 September 2019 | 2:00 am | Google News

Takeda issues recall of Natpara - BioPharma-Reporter.com

Takeda issues recall of Natpara  BioPharma-Reporter.com

Posted on 10 September 2019 | 2:00 am | Google News

Takeda issues US recall of NATPARA, a parathyroid hormone - BSA bureau

Takeda issues US recall of NATPARA, a parathyroid hormone  BSA bureau

Posted on 9 September 2019 | 2:00 am | Google News

Copyright © 2019 LastMinuteStuff.com | Contact info